2 most recent filings and news items mentioning CRBP. Updated every 60 seconds.
RegulatoryMay 26, 2026Positive
Corbus Pharmaceuticals announced updated Phase 1/2 data showing CRB-701 demonstrated robust activity in second-line oropharyngeal and cervical cancers with confirmed response rates of 42.9% and 34.4% respectively, with a favorable safety profile. The company plans to initiate a r
View filing at SEC.gov →
LeadershipMay 21, 2026Positive
Corbus Pharmaceuticals has entered into an employment agreement with Nishant Saxena to serve as Chief Business Officer, effective May 21, 2026, with an annual base salary of $470,000. The appointment reflects the company's leadership expansion in its business development and stra
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.